478 related articles for article (PubMed ID: 28780700)
1. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
4. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
[TBL] [Abstract][Full Text] [Related]
5. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
8. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Sun C; Sun H; Zhang C; Tian Z
Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
10. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
12. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
13. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
14. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
15. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
16. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model.
Dai K; Huang Y; Chen Z; Sun X; Yang L; Jiang Y
Eur J Immunol; 2018 Apr; 48(4):683-695. PubMed ID: 29331106
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.
Jacquelot N; Seillet C; Souza-Fonseca-Guimaraes F; Sacher AG; Belz GT; Ohashi PS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445750
[TBL] [Abstract][Full Text] [Related]
18. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
19. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy.
Tanimine N; Tanaka Y; Kobayashi T; Tashiro H; Miki D; Imamura M; Aikata H; Tanaka J; Chayama K; Ohdan H
Cancer Immunol Res; 2014 Dec; 2(12):1142-7. PubMed ID: 25135909
[TBL] [Abstract][Full Text] [Related]
20. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
